Here is the rundown on market activity for United Therapeutics Corporation (NASDAQ:UTHR). Martine A. Rothblatt, Chairman sold $161,188 worth of shares at an average price of $130.20 on June 15th. Rothblatt now owns $18,228 of stock as recorded in a recent Form 4 SEC filing. Chairman Martine A. Rothblatt disclosed the sale of 1,240 shares. The shares were sold on June 8th for an average price of $129.78. Rothblatt now owns $18,169 of the stock according to the SEC filing.
Martine A. Rothblatt, Chairman reported the sale of 1,251 shares of (UTHR). The shares were purchased at an average price of $124.48. The Chairman now owns $17,427 of the stock per the Form 4 SEC filing.
United Therapeutics Corporation, launched on June 26, 1996, is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca)..
Here are some other firms who have updated their holdings. Proficio Capital Partners LLC augmented its holdings by buying 64 shares an increase of 58.2% in the quarter. Proficio Capital Partners LLC now controls 174 shares valued at $21,000. The total value of its holdings increased 31.3%. As of the end of the quarter Morgan Stanley had sold a total of 2,137 shares trimming its holdings by 12.9%. The value of the total investment in United Therapeutics Corporation went from $2,379,000 to $1,956,000 decreasing 17.8% for the reporting period.
Winton Group Ltd trimmed its stake by selling 12,635 shares a decrease of 7.1% from 12/31/2016 to 03/31/2017. Winton Group Ltd now controls 165,735 shares with a value of $22,437,000. The value of the position overall is down by 12.3%. As of the end of the quarter Tower Research Capital LLC (trc) had bought 205 shares growing its stake by 1,576.9%. The value of the company’s investment in United Therapeutics Corporation went from $2,000 to $30,000 a change of $28,000 since the last quarter.
Equity analyst Oppenheimer began coverage by announcing an initial rating of “Outperform”. On November 29 the company was downgraded from “Equal-weight” to “Underweight” in an announcement from Barclays.
On October 28 the stock rating was upgraded to “Buy” from “Neutral” and a price target of $138.00 was set by Ladenburg Thalmann. On June 15 the stock rating was downgraded to “Neutral” from “” with a current price target of $95.00 in a statement from H.C. Wainwright.
On May 24, 2016 the stock rating was rated “Hold” in a report from Argus Research down from the previous “Buy” rating. On April 29 the company was changed to a “Neutral” by Ladenburg Thalmann which is down from the previous “” rating.
The company is now unchanged since yesterday’s close of $129.92. Company shares last traded at $129.92 slightly over the 50 day moving average of $124.34 and marginally under the 200 day moving average of $138.37. The 50 day moving average went up $5.58 or +4.49% whereas the 200 day moving average was down $-8.45 or -6.11%.
United Therapeutics Corporation currently has a P/E ratio of 9.12 and the market value is 5.85B. In the latest earnings report the EPS was $14.24 and is projected to be $14.42 for the current year with 45,056,000 shares now outstanding. Next quarter’s EPS is expected be $3.69 with next year’s EPS anticipated to be $11.03.
Short traders are feeling a little more bullish on shares of United Therapeutics Corporation if you look at the decrease in short interest. The stock had a fall in short interest of -3.03% as of May 15, 2017 from the last reporting period. Short shares fell 185,383 over that timeframe. With short interest at 5,939,312 and short average daily volume at 460,582, the short-interest ratio is 12.9 and the percentage of shorted shares was 0.13% on May 15.